Risk of depression and anemia in users of hormonal endometriosis treatments: Results from the VIPOS study

Dienogest (DNG) 2  mg (Visanne) was approved for endometriosis treatment in Europe in 2010. The Visanne Post-approval Observational Study (VIPOS) was designed to assess the safety of DNG 2 mg/day compared to other hormonal endometriosis treatments, focusing especially on clinically relevant depression and anemia.

Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - June 1, 2020 Category: OBGYN Authors: Sabine Moehner, Kerstin Becker, Jens A. Lange, Sophia von Stockum, Klaas Heinemann Tags: Full length article Source Type: research